Marker Therapeutics (MRKR) Competitors

$1.46 +0.03 (+2.10%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$1.46 0.00 (-0.34%)

As of 04:18 AM Eastern

MRKR vs. ANIX, PMN, LONA, QTTB, and AADI

Should you buy Marker Therapeutics stock or one of its competitors? MarketBeat compares Marker Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marker Therapeutics include Anixa Biosciences (ANIX), Promis Neurosciences (PMN), Athira Pharma (LONA), Q32 Bio (QTTB), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

How does Marker Therapeutics compare to Anixa Biosciences?

Marker Therapeutics (NASDAQ:MRKR) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

In the previous week, Anixa Biosciences had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Anixa Biosciences and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.94 beat Anixa Biosciences' score of 0.62 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anixa Biosciences has lower revenue, but higher earnings than Marker Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.85	N/A
Anixa Biosciences	$210K	461.44	-$10.93M	-$0.33	N/A

Anixa Biosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Anixa Biosciences' return on equity of -70.95% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-80.86%	-67.04%
Anixa Biosciences	N/A	-70.95%	-62.53%

Marker Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 584.93%. Anixa Biosciences has a consensus price target of $8.50, suggesting a potential upside of 194.12%. Given Marker Therapeutics' higher possible upside, equities analysts plainly believe Marker Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Marker Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Anixa Biosciences beats Marker Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to Promis Neurosciences?

Marker Therapeutics (NASDAQ:MRKR) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Promis Neurosciences had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 4 mentions for Promis Neurosciences and 2 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.94 beat Promis Neurosciences' score of -0.28 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Marker Therapeutics has higher revenue and earnings than Promis Neurosciences. Marker Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.85	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$19.00	N/A

Promis Neurosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -80.86% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-80.86%	-67.04%
Promis Neurosciences	N/A	-237.99%	-151.04%

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 584.93%. Promis Neurosciences has a consensus target price of $26.50, suggesting a potential upside of 150.47%. Given Marker Therapeutics' higher probable upside, research analysts clearly believe Marker Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Marker Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.2, suggesting that its share price is 120% less volatile than the broader market.

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Marker Therapeutics beats Promis Neurosciences on 9 of the 14 factors compared between the two stocks.

How does Marker Therapeutics compare to Athira Pharma?

Marker Therapeutics (NASDAQ:MRKR) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by insiders. Comparatively, 25.1% of Athira Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Athira Pharma has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -80.86% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-80.86%	-67.04%
Athira Pharma	N/A	-381.01%	-225.74%

Marker Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 584.93%. Athira Pharma has a consensus target price of $10.00, suggesting a potential downside of 9.09%. Given Marker Therapeutics' higher probable upside, research analysts clearly believe Marker Therapeutics is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Marker Therapeutics had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Marker Therapeutics and 1 mentions for Athira Pharma. Marker Therapeutics' average media sentiment score of 0.94 beat Athira Pharma's score of 0.74 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Marker Therapeutics	Positive
Athira Pharma	Positive

Marker Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

Marker Therapeutics has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.85	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Summary

Marker Therapeutics beats Athira Pharma on 9 of the 13 factors compared between the two stocks.

How does Marker Therapeutics compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Q32 Bio has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Q32 Bio's return on equity of 149.23% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
Marker Therapeutics	-343.03%	-80.86%	-67.04%

Q32 Bio currently has a consensus target price of $13.00, suggesting a potential upside of 108.00%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 584.93%. Given Marker Therapeutics' higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Q32 Bio and Q32 Bio both had 2 articles in the media. Q32 Bio's average media sentiment score of 1.04 beat Marker Therapeutics' score of 0.94 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Q32 Bio has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	1.97	$29.82M	$2.66	2.35
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.85	N/A

Summary

Q32 Bio beats Marker Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aadi Bioscience has a net margin of -246.06% compared to Marker Therapeutics' net margin of -343.03%. Aadi Bioscience's return on equity of -71.87% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Marker Therapeutics	-343.03%	-80.86%	-67.04%

Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 584.93%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Marker Therapeutics had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 2 mentions for Marker Therapeutics and 0 mentions for Aadi Bioscience. Marker Therapeutics' average media sentiment score of 0.94 beat Aadi Bioscience's score of 0.67 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Positive
Marker Therapeutics	Positive

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Marker Therapeutics has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.86	-$65.76M	-$2.35	N/A
Marker Therapeutics	$3.55M	6.86	-$12.16M	-$0.85	N/A

Summary

Marker Therapeutics beats Aadi Bioscience on 10 of the 16 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.84M	$3.06B	$6.34B	$12.37B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-1.72	18.70	20.66	25.63
Price / Sales	6.86	271.92	547.02	76.59
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	1.45	4.42	9.93	6.97
Net Income	-$12.16M	$72.19M	$3.55B	$333.62M
7 Day Performance	N/A	-0.43%	1.69%	1.09%
1 Month Performance	-7.59%	-0.96%	0.48%	3.08%
1 Year Performance	29.20%	45.81%	39.38%	35.68%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	3.1012 of 5 stars	$1.46 +2.1%	$10.00 +584.9%	+30.4%	$23.84M	$3.55M	N/A	60	News Coverage Upcoming Earnings
ANIX Anixa Biosciences	2.248 of 5 stars	$2.88 -5.0%	$8.50 +195.1%	+13.3%	$96.57M	$210K	N/A	5
PMN Promis Neurosciences	2.657 of 5 stars	$10.59 -0.9%	$26.50 +150.4%	-16.2%	$94.95M	N/A	N/A	5	Earnings Report
LONA Athira Pharma	1.7122 of 5 stars	$9.90 -1.1%	$10.00 +1.0%	N/A	$94.64M	N/A	N/A	40	Negative News
QTTB Q32 Bio	3.9666 of 5 stars	$5.57 +7.5%	$13.00 +133.4%	+278.8%	$94.43M	$53.74M	2.09	39	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. ANIX, PMN, LONA, QTTB, and AADI

How does Marker Therapeutics compare to Anixa Biosciences?

Summary

How does Marker Therapeutics compare to Promis Neurosciences?

Summary

How does Marker Therapeutics compare to Athira Pharma?

Summary

How does Marker Therapeutics compare to Q32 Bio?

Summary

How does Marker Therapeutics compare to Aadi Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. ANIX, PMN, LONA, QTTB, and AADI

How does Marker Therapeutics compare to Anixa Biosciences?

Does the media refer more to MRKR or ANIX?

Which has higher earnings and valuation, MRKR or ANIX?

Is MRKR or ANIX more profitable?

Do analysts recommend MRKR or ANIX?

Which has more risk and volatility, MRKR or ANIX?

Do institutionals & insiders have more ownership in MRKR or ANIX?

Summary

How does Marker Therapeutics compare to Promis Neurosciences?

Does the media prefer MRKR or PMN?

Which has stronger earnings & valuation, MRKR or PMN?

Is MRKR or PMN more profitable?

Do analysts prefer MRKR or PMN?

Which has more volatility & risk, MRKR or PMN?

Do insiders and institutionals have more ownership in MRKR or PMN?

Summary

How does Marker Therapeutics compare to Athira Pharma?

Do insiders and institutionals have more ownership in MRKR or LONA?

Is MRKR or LONA more profitable?

Do analysts prefer MRKR or LONA?

Does the media prefer MRKR or LONA?

Which has more volatility & risk, MRKR or LONA?

Which has stronger earnings & valuation, MRKR or LONA?

Summary

How does Marker Therapeutics compare to Q32 Bio?

Do institutionals and insiders hold more shares of QTTB or MRKR?

Is QTTB or MRKR more profitable?

Do analysts rate QTTB or MRKR?

Does the media favor QTTB or MRKR?

Which has more volatility & risk, QTTB or MRKR?

Which has preferable valuation & earnings, QTTB or MRKR?

Summary

How does Marker Therapeutics compare to Aadi Bioscience?

Do institutionals and insiders hold more shares of AADI or MRKR?

Is AADI or MRKR more profitable?

Do analysts rate AADI or MRKR?

Does the media favor AADI or MRKR?

Which has more volatility & risk, AADI or MRKR?

Which has preferable valuation & earnings, AADI or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools